APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained Release Injectables

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Sustained Release Injectables Market Analysis and Forecast 2026-2032

20 December 2025217 pages

Choose your research edition.

Industry ResearchSustained Release Injectables Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained Release Injectables Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Sustained Release Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained Release Injectables Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained Release Injectables Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Sustained Release Injectables market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Sustained Release Injectables is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Sustained Release Injectables is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Sustained Release Injectables is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Sustained Release Injectables is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Sustained Release Injectables include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Sustained Release Injectables, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Sustained Release Injectables, also provides the revenue of main regions and countries. Of the upcoming market potential for Sustained Release Injectables, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Sustained Release Injectables revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Sustained Release Injectables market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Sustained Release Injectables revenue, projected growth trends, production technology, application and end-user industry.

Sustained Release Injectables Segment by Company

Sanofi

Novartis

Merck

Luye Pharma Group

Roche

Livzon Pharm

Eli Lilly

AstraZeneca

Xbrane Biopharma

Taiwan Liposome Company (TLC)

Recipharm AB

PhaseBio Pharmaceuticals

Pacira

OctoPlus

Oakwood Laboratories/PharmaSophia

NanOlogy

Janssen

Ipsen

InnoCore Pharmaceuticals

Enzon

Durect

Critical Pharmaceuticals

Camurus

Biomarin

Avadel

Aurobindo

Ascendis Pharma

AntriaBio

Amylin Pharmaceuticals

Alkermes

Sustained Release Injectables Segment by Type

Gels

Microparticles

Implants

Sustained Release Injectables Segment by Application

Oncology

CNS

Acromegaly

Ophthalmology

Diabetes

Reproductive Health

Rheumatology

Leukemia

Others

Sustained Release Injectables Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Sustained Release Injectables in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Sustained Release Injectables company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sustained Release Injectables revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sustained Release Injectables Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Gels Major Player Table 3. Microparticles Major Player Table 4. Implants Major Player Table 5. Global Sustained Release Injectables Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Oncology Major Player Table 7. CNS Major Player Table 8. Acromegaly Major Player Table 9. Ophthalmology Major Player Table 10. Diabetes Major Player Table 11. Reproductive Health Major Player Table 12. Rheumatology Major Player Table 13. Leukemia Major Player Table 14. Others Major Player Table 15. Sustained Release Injectables Industry Trends Table 16. Sustained Release Injectables Industry Drivers Table 17. Sustained Release Injectables Industry Opportunities and Challenges Table 18. Sustained Release Injectables Industry Restraints Table 19. Global Sustained Release Injectables Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 20. Global Sustained Release Injectables Market Size by Region (2021-2026) & (US$ Million) Table 21. Global Sustained Release Injectables Market Share by Region (2021-2026) Table 22. Global Sustained Release Injectables Market Size by Region (2027-2032) & (US$ Million) Table 23. Global Sustained Release Injectables Market Share by Region (2027-2032) Table 24. Global Sustained Release Injectables Revenue by Players (US$ Million) & (2021-2026) Table 25. Global Sustained Release Injectables Revenue Market Share by Players (2021-2026) Table 26. Global Sustained Release Injectables Key Players Ranking, 2024 VS 2025 VS 2026 Table 27. Global Sustained Release Injectables Key Players Headquarters & Area Served Table 28. Global Sustained Release Injectables Players, Product Type & Application Table 29. Global Sustained Release Injectables Players Establishment Date Table 30. Global Players Market Concentration Ratio (CR5 and HHI) Table 31. Global Sustained Release Injectables by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Sustained Release Injectables Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Sustained Release Injectables Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Sustained Release Injectables Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Sustained Release Injectables Revenue Market Share by Type (2021-2026) Table 36. Global Sustained Release Injectables Revenue Market Share by Type (2027-2032) Table 37. Global Sustained Release Injectables Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Sustained Release Injectables Revenue by Application (2021-2026) & (US$ Million) Table 39. Global Sustained Release Injectables Revenue by Application (2027-2032) & (US$ Million) Table 40. Global Sustained Release Injectables Revenue Market Share by Application (2021-2026) Table 41. Global Sustained Release Injectables Revenue Market Share by Application (2027-2032) Table 42. Sanofi Company Information Table 43. Sanofi Business Overview Table 44. Sanofi Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sanofi Sustained Release Injectables Product Portfolio Table 46. Sanofi Recent Development Table 47. Novartis Company Information Table 48. Novartis Business Overview Table 49. Novartis Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Novartis Sustained Release Injectables Product Portfolio Table 51. Novartis Recent Development Table 52. Merck Company Information Table 53. Merck Business Overview Table 54. Merck Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Merck Sustained Release Injectables Product Portfolio Table 56. Merck Recent Development Table 57. Luye Pharma Group Company Information Table 58. Luye Pharma Group Business Overview Table 59. Luye Pharma Group Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Luye Pharma Group Sustained Release Injectables Product Portfolio Table 61. Luye Pharma Group Recent Development Table 62. Roche Company Information Table 63. Roche Business Overview Table 64. Roche Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Roche Sustained Release Injectables Product Portfolio Table 66. Roche Recent Development Table 67. Livzon Pharm Company Information Table 68. Livzon Pharm Business Overview Table 69. Livzon Pharm Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Livzon Pharm Sustained Release Injectables Product Portfolio Table 71. Livzon Pharm Recent Development Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Eli Lilly Sustained Release Injectables Product Portfolio Table 76. Eli Lilly Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. AstraZeneca Sustained Release Injectables Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Xbrane Biopharma Company Information Table 83. Xbrane Biopharma Business Overview Table 84. Xbrane Biopharma Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Xbrane Biopharma Sustained Release Injectables Product Portfolio Table 86. Xbrane Biopharma Recent Development Table 87. Taiwan Liposome Company (TLC) Company Information Table 88. Taiwan Liposome Company (TLC) Business Overview Table 89. Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio Table 91. Taiwan Liposome Company (TLC) Recent Development Table 92. Recipharm AB Company Information Table 93. Recipharm AB Business Overview Table 94. Recipharm AB Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Recipharm AB Sustained Release Injectables Product Portfolio Table 96. Recipharm AB Recent Development Table 97. PhaseBio Pharmaceuticals Company Information Table 98. PhaseBio Pharmaceuticals Business Overview Table 99. PhaseBio Pharmaceuticals Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio Table 101. PhaseBio Pharmaceuticals Recent Development Table 102. Pacira Company Information Table 103. Pacira Business Overview Table 104. Pacira Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Pacira Sustained Release Injectables Product Portfolio Table 106. Pacira Recent Development Table 107. OctoPlus Company Information Table 108. OctoPlus Business Overview Table 109. OctoPlus Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. OctoPlus Sustained Release Injectables Product Portfolio Table 111. OctoPlus Recent Development Table 112. Oakwood Laboratories/PharmaSophia Company Information Table 113. Oakwood Laboratories/PharmaSophia Business Overview Table 114. Oakwood Laboratories/PharmaSophia Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio Table 116. Oakwood Laboratories/PharmaSophia Recent Development Table 117. NanOlogy Company Information Table 118. NanOlogy Business Overview Table 119. NanOlogy Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. NanOlogy Sustained Release Injectables Product Portfolio Table 121. NanOlogy Recent Development Table 122. Janssen Company Information Table 123. Janssen Business Overview Table 124. Janssen Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Janssen Sustained Release Injectables Product Portfolio Table 126. Janssen Recent Development Table 127. Ipsen Company Information Table 128. Ipsen Business Overview Table 129. Ipsen Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Ipsen Sustained Release Injectables Product Portfolio Table 131. Ipsen Recent Development Table 132. InnoCore Pharmaceuticals Company Information Table 133. InnoCore Pharmaceuticals Business Overview Table 134. InnoCore Pharmaceuticals Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio Table 136. InnoCore Pharmaceuticals Recent Development Table 137. Enzon Company Information Table 138. Enzon Business Overview Table 139. Enzon Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. Enzon Sustained Release Injectables Product Portfolio Table 141. Enzon Recent Development Table 142. Durect Company Information Table 143. Durect Business Overview Table 144. Durect Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 145. Durect Sustained Release Injectables Product Portfolio Table 146. Durect Recent Development Table 147. Critical Pharmaceuticals Company Information Table 148. Critical Pharmaceuticals Business Overview Table 149. Critical Pharmaceuticals Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 150. Critical Pharmaceuticals Sustained Release Injectables Product Portfolio Table 151. Critical Pharmaceuticals Recent Development Table 152. Camurus Company Information Table 153. Camurus Business Overview Table 154. Camurus Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 155. Camurus Sustained Release Injectables Product Portfolio Table 156. Camurus Recent Development Table 157. Biomarin Company Information Table 158. Biomarin Business Overview Table 159. Biomarin Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 160. Biomarin Sustained Release Injectables Product Portfolio Table 161. Biomarin Recent Development Table 162. Avadel Company Information Table 163. Avadel Business Overview Table 164. Avadel Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 165. Avadel Sustained Release Injectables Product Portfolio Table 166. Avadel Recent Development Table 167. Aurobindo Company Information Table 168. Aurobindo Business Overview Table 169. Aurobindo Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 170. Aurobindo Sustained Release Injectables Product Portfolio Table 171. Aurobindo Recent Development Table 172. Ascendis Pharma Company Information Table 173. Ascendis Pharma Business Overview Table 174. Ascendis Pharma Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 175. Ascendis Pharma Sustained Release Injectables Product Portfolio Table 176. Ascendis Pharma Recent Development Table 177. AntriaBio Company Information Table 178. AntriaBio Business Overview Table 179. AntriaBio Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 180. AntriaBio Sustained Release Injectables Product Portfolio Table 181. AntriaBio Recent Development Table 182. Amylin Pharmaceuticals Company Information Table 183. Amylin Pharmaceuticals Business Overview Table 184. Amylin Pharmaceuticals Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 185. Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio Table 186. Amylin Pharmaceuticals Recent Development Table 187. Alkermes Company Information Table 188. Alkermes Business Overview Table 189. Alkermes Sustained Release Injectables Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 190. Alkermes Sustained Release Injectables Product Portfolio Table 191. Alkermes Recent Development Table 192. North America Sustained Release Injectables Revenue by Type (2021-2026) & (US$ Million) Table 193. North America Sustained Release Injectables Revenue by Type (2027-2032) & (US$ Million) Table 194. North America Sustained Release Injectables Revenue by Application (2021-2026) & (US$ Million) Table 195. North America Sustained Release Injectables Revenue by Application (2027-2032) & (US$ Million) Table 196. North America Sustained Release Injectables Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. North America Sustained Release Injectables Revenue by Country (2021-2026) & (US$ Million) Table 198. North America Sustained Release Injectables Revenue by Country (US$ Million) & (2027-2032) Table 199. Europe Sustained Release Injectables Revenue by Type (2021-2026) & (US$ Million) Table 200. Europe Sustained Release Injectables Revenue by Type (2027-2032) & (US$ Million) Table 201. Europe Sustained Release Injectables Revenue by Application (2021-2026) & (US$ Million) Table 202. Europe Sustained Release Injectables Revenue by Application (2027-2032) & (US$ Million) Table 203. Europe Sustained Release Injectables Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. Europe Sustained Release Injectables Revenue by Country (2021-2026) & (US$ Million) Table 205. Europe Sustained Release Injectables Revenue by Country (US$ Million) & (2027-2032) Table 206. China Sustained Release Injectables Revenue by Type (2021-2026) & (US$ Million) Table 207. China Sustained Release Injectables Revenue by Type (2027-2032) & (US$ Million) Table 208. China Sustained Release Injectables Revenue by Application (2021-2026) & (US$ Million) Table 209. China Sustained Release Injectables Revenue by Application (2027-2032) & (US$ Million) Table 210. Asia Sustained Release Injectables Revenue by Type (2021-2026) & (US$ Million) Table 211. Asia Sustained Release Injectables Revenue by Type (2027-2032) & (US$ Million) Table 212. Asia Sustained Release Injectables Revenue by Application (2021-2026) & (US$ Million) Table 213. Asia Sustained Release Injectables Revenue by Application (2027-2032) & (US$ Million) Table 214. Asia Sustained Release Injectables Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 215. Asia Sustained Release Injectables Revenue by Region (US$ Million) & (2021-2026) Table 216. Asia Sustained Release Injectables Revenue by Region (US$ Million) & (2027-2032) Table 217. SAMEA Sustained Release Injectables Revenue by Type (2021-2026) & (US$ Million) Table 218. SAMEA Sustained Release Injectables Revenue by Type (2027-2032) & (US$ Million) Table 219. SAMEA Sustained Release Injectables Revenue by Application (2021-2026) & (US$ Million) Table 220. SAMEA Sustained Release Injectables Revenue by Application (2027-2032) & (US$ Million) Table 221. SAMEA Sustained Release Injectables Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 222. SAMEA Sustained Release Injectables Revenue by Country (2021-2026) & (US$ Million) Table 223. SAMEA Sustained Release Injectables Revenue by Country (US$ Million) & (2027-2032) Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Sustained Release Injectables Image Figure 2. Global Sustained Release Injectables Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sustained Release Injectables Market Size Share 2021 VS 2025 VS 2032 Figure 4. Gels Image Figure 5. Microparticles Image Figure 6. Implants Image Figure 7. Global Sustained Release Injectables Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Sustained Release Injectables Market Size Share 2021 VS 2025 VS 2032 Figure 9. Oncology Image Figure 10. CNS Image Figure 11. Acromegaly Image Figure 12. Ophthalmology Image Figure 13. Diabetes Image Figure 14. Reproductive Health Image Figure 15. Rheumatology Image Figure 16. Leukemia Image Figure 17. Others Image Figure 18. Global Sustained Release Injectables Market Size (US$ Million) & (2021-2032) Figure 19. Global Sustained Release Injectables Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 20. Global Sustained Release Injectables Market Share by Region: 2021 VS 2025 VS 2032 Figure 21. Global Sustained Release Injectables Players Revenue Share Top 10 and Top 5 in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Sustained Release Injectables Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Sustained Release Injectables Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Sustained Release Injectables Revenue Market Share by Type (2021-2032) Figure 26. Global Sustained Release Injectables Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Sustained Release Injectables Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 28. Global Sustained Release Injectables Revenue Market Share by Application (2021-2032) Figure 29. North America Sustained Release Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. North America Sustained Release Injectables Revenue Share by Type (2021-2032) Figure 31. North America Sustained Release Injectables Revenue Share by Application (2021-2032) Figure 32. North America Sustained Release Injectables Revenue Share by Country (2021-2032) Figure 33. United States Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Canada Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Mexico Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Europe Sustained Release Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 37. Europe Sustained Release Injectables Revenue Share by Type (2021-2032) Figure 38. Europe Sustained Release Injectables Revenue Share by Application (2021-2032) Figure 39. Europe Sustained Release Injectables Revenue Share by Country (2021-2032) Figure 40. Germany Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. France Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. U.K. Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Italy Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Spain Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Russia Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Netherlands Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Nordic Countries Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. China Sustained Release Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. China Sustained Release Injectables Revenue Share by Type (2021-2032) Figure 50. China Sustained Release Injectables Revenue Share by Application (2021-2032) Figure 51. Asia Sustained Release Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 52. Asia Sustained Release Injectables Revenue Share by Type (2021-2032) Figure 53. Asia Sustained Release Injectables Revenue Share by Application (2021-2032) Figure 54. Asia Sustained Release Injectables Revenue Share by Region (2021-2032) Figure 55. Japan Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. South Korea Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. India Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Australia Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Taiwan Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Southeast Asia Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. SAMEA Sustained Release Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 62. SAMEA Sustained Release Injectables Revenue Share by Type (2021-2032) Figure 63. SAMEA Sustained Release Injectables Revenue Share by Application (2021-2032) Figure 64. SAMEA Sustained Release Injectables Revenue Share by Country (2021-2032) Figure 65. Brazil Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Argentina Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Chile Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Colombia Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Peru Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Saudi Arabia Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Israel Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. UAE Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Turkey Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Iran Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Egypt Sustained Release Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Gels
  • Microparticles
  • Implants
Applications
  • Oncology
  • CNS
  • Acromegaly
  • Ophthalmology
  • Diabetes
  • Reproductive Health
  • Rheumatology
  • Leukemia
  • Others
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Luye Pharma Group
  • Roche
  • Livzon Pharm
  • Eli Lilly
  • AstraZeneca
  • Xbrane Biopharma
  • Taiwan Liposome Company (TLC)
  • Recipharm AB
  • PhaseBio Pharmaceuticals
  • Pacira
  • OctoPlus
  • Oakwood Laboratories/PharmaSophia
  • NanOlogy
  • Janssen
  • Ipsen
  • InnoCore Pharmaceuticals
  • Enzon
  • Durect
  • Critical Pharmaceuticals
  • Camurus
  • Biomarin
  • Avadel
  • Aurobindo
  • Ascendis Pharma
  • AntriaBio
  • Amylin Pharmaceuticals
  • Alkermes

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Sustained Release Injectables Market by Type
  3. 1.2.1 Global Sustained Release Injectables Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Gels
  5. 1.2.3 Microparticles
  6. 1.2.4 Implants
  7. 1.3 Sustained Release Injectables Market by Application
  8. 1.3.1 Global Sustained Release Injectables Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 CNS
  11. 1.3.4 Acromegaly
  12. 1.3.5 Ophthalmology
  13. 1.3.6 Diabetes
  14. 1.3.7 Reproductive Health
  15. 1.3.8 Rheumatology
  16. 1.3.9 Leukemia
  17. 1.3.10 Others
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Sustained Release Injectables Market Dynamics
  1. 2.1 Sustained Release Injectables Industry Trends
  2. 2.2 Sustained Release Injectables Industry Drivers
  3. 2.3 Sustained Release Injectables Industry Opportunities and Challenges
  4. 2.4 Sustained Release Injectables Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Sustained Release Injectables Market Perspective (2021-2032)
  2. 3.2 Global Sustained Release Injectables Growth Trends by Region
  3. 3.2.1 Global Sustained Release Injectables Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Sustained Release Injectables Market Size by Region (2021-2026)
  5. 3.2.3 Global Sustained Release Injectables Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Sustained Release Injectables Revenue by Players
  2. 4.1.1 Global Sustained Release Injectables Revenue by Players (2021-2026)
  3. 4.1.2 Global Sustained Release Injectables Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Sustained Release Injectables Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Sustained Release Injectables Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Sustained Release Injectables Key Players Headquarters & Area Served
  7. 4.4 Global Sustained Release Injectables Players, Product Type & Application
  8. 4.5 Global Sustained Release Injectables Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Sustained Release Injectables Market CR5 and HHI
  11. 4.6.3 2025 Sustained Release Injectables Tier 1, Tier 2, and Tier 3
5 Sustained Release Injectables Market Size by Type
  1. 5.1 Global Sustained Release Injectables Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Sustained Release Injectables Revenue by Type (2021-2032)
  3. 5.3 Global Sustained Release Injectables Revenue Market Share by Type (2021-2032)
6 Sustained Release Injectables Market Size by Application
  1. 6.1 Global Sustained Release Injectables Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Sustained Release Injectables Revenue by Application (2021-2032)
  3. 6.3 Global Sustained Release Injectables Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Sustained Release Injectables Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Sustained Release Injectables Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Sustained Release Injectables Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Luye Pharma Group
  20. 7.4.1 Luye Pharma Group Company Information
  21. 7.4.2 Luye Pharma Group Business Overview
  22. 7.4.3 Luye Pharma Group Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Luye Pharma Group Sustained Release Injectables Product Portfolio
  24. 7.4.5 Luye Pharma Group Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Sustained Release Injectables Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Livzon Pharm
  32. 7.6.1 Livzon Pharm Company Information
  33. 7.6.2 Livzon Pharm Business Overview
  34. 7.6.3 Livzon Pharm Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Livzon Pharm Sustained Release Injectables Product Portfolio
  36. 7.6.5 Livzon Pharm Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Sustained Release Injectables Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 AstraZeneca
  44. 7.8.1 AstraZeneca Company Information
  45. 7.8.2 AstraZeneca Business Overview
  46. 7.8.3 AstraZeneca Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AstraZeneca Sustained Release Injectables Product Portfolio
  48. 7.8.5 AstraZeneca Recent Developments
  49. 7.9 Xbrane Biopharma
  50. 7.9.1 Xbrane Biopharma Company Information
  51. 7.9.2 Xbrane Biopharma Business Overview
  52. 7.9.3 Xbrane Biopharma Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Xbrane Biopharma Sustained Release Injectables Product Portfolio
  54. 7.9.5 Xbrane Biopharma Recent Developments
  55. 7.10 Taiwan Liposome Company (TLC)
  56. 7.10.1 Taiwan Liposome Company (TLC) Company Information
  57. 7.10.2 Taiwan Liposome Company (TLC) Business Overview
  58. 7.10.3 Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
  60. 7.10.5 Taiwan Liposome Company (TLC) Recent Developments
  61. 7.11 Recipharm AB
  62. 7.11.1 Recipharm AB Company Information
  63. 7.11.2 Recipharm AB Business Overview
  64. 7.11.3 Recipharm AB Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Recipharm AB Sustained Release Injectables Product Portfolio
  66. 7.11.5 Recipharm AB Recent Developments
  67. 7.12 PhaseBio Pharmaceuticals
  68. 7.12.1 PhaseBio Pharmaceuticals Company Information
  69. 7.12.2 PhaseBio Pharmaceuticals Business Overview
  70. 7.12.3 PhaseBio Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  71. 7.12.4 PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
  72. 7.12.5 PhaseBio Pharmaceuticals Recent Developments
  73. 7.13 Pacira
  74. 7.13.1 Pacira Company Information
  75. 7.13.2 Pacira Business Overview
  76. 7.13.3 Pacira Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Pacira Sustained Release Injectables Product Portfolio
  78. 7.13.5 Pacira Recent Developments
  79. 7.14 OctoPlus
  80. 7.14.1 OctoPlus Company Information
  81. 7.14.2 OctoPlus Business Overview
  82. 7.14.3 OctoPlus Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  83. 7.14.4 OctoPlus Sustained Release Injectables Product Portfolio
  84. 7.14.5 OctoPlus Recent Developments
  85. 7.15 Oakwood Laboratories/PharmaSophia
  86. 7.15.1 Oakwood Laboratories/PharmaSophia Company Information
  87. 7.15.2 Oakwood Laboratories/PharmaSophia Business Overview
  88. 7.15.3 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio
  90. 7.15.5 Oakwood Laboratories/PharmaSophia Recent Developments
  91. 7.16 NanOlogy
  92. 7.16.1 NanOlogy Company Information
  93. 7.16.2 NanOlogy Business Overview
  94. 7.16.3 NanOlogy Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  95. 7.16.4 NanOlogy Sustained Release Injectables Product Portfolio
  96. 7.16.5 NanOlogy Recent Developments
  97. 7.17 Janssen
  98. 7.17.1 Janssen Company Information
  99. 7.17.2 Janssen Business Overview
  100. 7.17.3 Janssen Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Janssen Sustained Release Injectables Product Portfolio
  102. 7.17.5 Janssen Recent Developments
  103. 7.18 Ipsen
  104. 7.18.1 Ipsen Company Information
  105. 7.18.2 Ipsen Business Overview
  106. 7.18.3 Ipsen Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Ipsen Sustained Release Injectables Product Portfolio
  108. 7.18.5 Ipsen Recent Developments
  109. 7.19 InnoCore Pharmaceuticals
  110. 7.19.1 InnoCore Pharmaceuticals Company Information
  111. 7.19.2 InnoCore Pharmaceuticals Business Overview
  112. 7.19.3 InnoCore Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  113. 7.19.4 InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
  114. 7.19.5 InnoCore Pharmaceuticals Recent Developments
  115. 7.20 Enzon
  116. 7.20.1 Enzon Company Information
  117. 7.20.2 Enzon Business Overview
  118. 7.20.3 Enzon Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Enzon Sustained Release Injectables Product Portfolio
  120. 7.20.5 Enzon Recent Developments
  121. 7.21 Durect
  122. 7.21.1 Durect Company Information
  123. 7.21.2 Durect Business Overview
  124. 7.21.3 Durect Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Durect Sustained Release Injectables Product Portfolio
  126. 7.21.5 Durect Recent Developments
  127. 7.22 Critical Pharmaceuticals
  128. 7.22.1 Critical Pharmaceuticals Company Information
  129. 7.22.2 Critical Pharmaceuticals Business Overview
  130. 7.22.3 Critical Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
  132. 7.22.5 Critical Pharmaceuticals Recent Developments
  133. 7.23 Camurus
  134. 7.23.1 Camurus Company Information
  135. 7.23.2 Camurus Business Overview
  136. 7.23.3 Camurus Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Camurus Sustained Release Injectables Product Portfolio
  138. 7.23.5 Camurus Recent Developments
  139. 7.24 Biomarin
  140. 7.24.1 Biomarin Company Information
  141. 7.24.2 Biomarin Business Overview
  142. 7.24.3 Biomarin Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Biomarin Sustained Release Injectables Product Portfolio
  144. 7.24.5 Biomarin Recent Developments
  145. 7.25 Avadel
  146. 7.25.1 Avadel Company Information
  147. 7.25.2 Avadel Business Overview
  148. 7.25.3 Avadel Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  149. 7.25.4 Avadel Sustained Release Injectables Product Portfolio
  150. 7.25.5 Avadel Recent Developments
  151. 7.26 Aurobindo
  152. 7.26.1 Aurobindo Company Information
  153. 7.26.2 Aurobindo Business Overview
  154. 7.26.3 Aurobindo Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Aurobindo Sustained Release Injectables Product Portfolio
  156. 7.26.5 Aurobindo Recent Developments
  157. 7.27 Ascendis Pharma
  158. 7.27.1 Ascendis Pharma Company Information
  159. 7.27.2 Ascendis Pharma Business Overview
  160. 7.27.3 Ascendis Pharma Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  161. 7.27.4 Ascendis Pharma Sustained Release Injectables Product Portfolio
  162. 7.27.5 Ascendis Pharma Recent Developments
  163. 7.28 AntriaBio
  164. 7.28.1 AntriaBio Company Information
  165. 7.28.2 AntriaBio Business Overview
  166. 7.28.3 AntriaBio Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  167. 7.28.4 AntriaBio Sustained Release Injectables Product Portfolio
  168. 7.28.5 AntriaBio Recent Developments
  169. 7.29 Amylin Pharmaceuticals
  170. 7.29.1 Amylin Pharmaceuticals Company Information
  171. 7.29.2 Amylin Pharmaceuticals Business Overview
  172. 7.29.3 Amylin Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  173. 7.29.4 Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio
  174. 7.29.5 Amylin Pharmaceuticals Recent Developments
  175. 7.30 Alkermes
  176. 7.30.1 Alkermes Company Information
  177. 7.30.2 Alkermes Business Overview
  178. 7.30.3 Alkermes Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  179. 7.30.4 Alkermes Sustained Release Injectables Product Portfolio
  180. 7.30.5 Alkermes Recent Developments
8 North America
  1. 8.1 North America Sustained Release Injectables Revenue (2021-2032)
  2. 8.2 North America Sustained Release Injectables Revenue by Type (2021-2032)
  3. 8.2.1 North America Sustained Release Injectables Revenue by Type (2021-2026)
  4. 8.2.2 North America Sustained Release Injectables Revenue by Type (2027-2032)
  5. 8.3 North America Sustained Release Injectables Revenue Share by Type (2021-2032)
  6. 8.4 North America Sustained Release Injectables Revenue by Application (2021-2032)
  7. 8.4.1 North America Sustained Release Injectables Revenue by Application (2021-2026)
  8. 8.4.2 North America Sustained Release Injectables Revenue by Application (2027-2032)
  9. 8.5 North America Sustained Release Injectables Revenue Share by Application (2021-2032)
  10. 8.6 North America Sustained Release Injectables Revenue by Country
  11. 8.6.1 North America Sustained Release Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Sustained Release Injectables Revenue by Country (2021-2026)
  13. 8.6.3 North America Sustained Release Injectables Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Sustained Release Injectables Revenue (2021-2032)
  2. 9.2 Europe Sustained Release Injectables Revenue by Type (2021-2032)
  3. 9.2.1 Europe Sustained Release Injectables Revenue by Type (2021-2026)
  4. 9.2.2 Europe Sustained Release Injectables Revenue by Type (2027-2032)
  5. 9.3 Europe Sustained Release Injectables Revenue Share by Type (2021-2032)
  6. 9.4 Europe Sustained Release Injectables Revenue by Application (2021-2032)
  7. 9.4.1 Europe Sustained Release Injectables Revenue by Application (2021-2026)
  8. 9.4.2 Europe Sustained Release Injectables Revenue by Application (2027-2032)
  9. 9.5 Europe Sustained Release Injectables Revenue Share by Application (2021-2032)
  10. 9.6 Europe Sustained Release Injectables Revenue by Country
  11. 9.6.1 Europe Sustained Release Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Sustained Release Injectables Revenue by Country (2021-2026)
  13. 9.6.3 Europe Sustained Release Injectables Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Sustained Release Injectables Revenue (2021-2032)
  2. 10.2 China Sustained Release Injectables Revenue by Type (2021-2032)
  3. 10.2.1 China Sustained Release Injectables Revenue by Type (2021-2026)
  4. 10.2.2 China Sustained Release Injectables Revenue by Type (2027-2032)
  5. 10.3 China Sustained Release Injectables Revenue Share by Type (2021-2032)
  6. 10.4 China Sustained Release Injectables Revenue by Application (2021-2032)
  7. 10.4.1 China Sustained Release Injectables Revenue by Application (2021-2026)
  8. 10.4.2 China Sustained Release Injectables Revenue by Application (2027-2032)
  9. 10.5 China Sustained Release Injectables Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Sustained Release Injectables Revenue (2021-2032)
  2. 11.2 Asia Sustained Release Injectables Revenue by Type (2021-2032)
  3. 11.2.1 Asia Sustained Release Injectables Revenue by Type (2021-2026)
  4. 11.2.2 Asia Sustained Release Injectables Revenue by Type (2027-2032)
  5. 11.3 Asia Sustained Release Injectables Revenue Share by Type (2021-2032)
  6. 11.4 Asia Sustained Release Injectables Revenue by Application (2021-2032)
  7. 11.4.1 Asia Sustained Release Injectables Revenue by Application (2021-2026)
  8. 11.4.2 Asia Sustained Release Injectables Revenue by Application (2027-2032)
  9. 11.5 Asia Sustained Release Injectables Revenue Share by Application (2021-2032)
  10. 11.6 Asia Sustained Release Injectables Revenue by Country
  11. 11.6.1 Asia Sustained Release Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Sustained Release Injectables Revenue by Country (2021-2026)
  13. 11.6.3 Asia Sustained Release Injectables Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Sustained Release Injectables Revenue (2021-2032)
  2. 12.2 SAMEA Sustained Release Injectables Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Sustained Release Injectables Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Sustained Release Injectables Revenue by Type (2027-2032)
  5. 12.3 SAMEA Sustained Release Injectables Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Sustained Release Injectables Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Sustained Release Injectables Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Sustained Release Injectables Revenue by Application (2027-2032)
  9. 12.5 SAMEA Sustained Release Injectables Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Sustained Release Injectables Revenue by Country
  11. 12.6.1 SAMEA Sustained Release Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Sustained Release Injectables Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Sustained Release Injectables Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst